A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

NCT00000671 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

750

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Zidovudine
DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]